A Study of ABT-751 in Patients With Renal Cell Cancer

Abbott60 enrolled

Overview

The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with renal cell cancer. Patients will receive ABT-751 by mouth daily for 21 days. Patients will be off drug for 7 days before starting the next cycle of drug.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Renal Cell Cancer

Interventions

ABT-751DRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria * Renal Cell Carcinoma. * Recurrent tumor. * At least 6 weeks post-nephrectomy. * Able to tolerate normal activities of daily living. * Adequate bone marrow, kidney, and liver function. Exclusion Criteria * Pregnant or breast feeding. * Anti-tumor therapy within 4 weeks of the start of ABT-751 administration. * CNS metastasis.

Locations (23)

Arizona Cancer Research Center

Tucson, Arizona, United States

Outcomes

Primary Outcomes

Objective Response Rate in subjects with RCC

Time frame: 1 year

Secondary Outcomes

Time to Tumor Progression (TTP)

Time frame: 1 year

Survival

Time frame: 2 years

Toxicities associated with treatment administration

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.